%0 Journal Article
%A Kersting, David
%A Sandach, Patrick
%A Sraieb, Miriam
%A Wiesweg, Marcel
%A Metzenmacher, Martin
%A Darwiche, Kaid
%A Oezkan, Filiz
%A Bölükbas, Servet
%A Stuschke, Martin
%A Umutlu, Lale
%A Nader, Michael
%A Hamacher, Rainer
%A Fendler, Wolfgang P
%A Wienker, Johannes
%A Eberhardt, Wilfried E E
%A Schuler, Martin
%A Herrmann, Ken
%A Hautzel, Hubertus
%T 68Ga-SSO-120 PET for Initial Staging of Small Cell Lung Cancer Patients: A Single-Center Retrospective Study.
%J Journal of nuclear medicine
%V 64
%N 10
%@ 0097-9058
%C New York, NY
%I Soc.
%M DKFZ-2023-01551
%P 1540-1549
%D 2023
%Z 2023 Oct;64(10):1540-1549
%X PET imaging using the somatostatin receptor 2 (SSTR2) antagonist satoreotide trizoxetan (SSO-120, previously OPS-202) could offer accurate tumor detection and screening for SSTR2-antagonist radionuclide therapy in patients with SSTR2-expressing small cell lung cancer (SCLC). The aim of this single-center study was to investigate tumor uptake and detection rates of 68Ga-SSO-120 in comparison to 18F-FDG PET in the initial staging of SCLC patients. Methods: Patients with newly diagnosed SCLC who underwent additional whole-body 68Ga-SSO-120 PET/CT during the initial diagnostic workup were retrospectively included. The mean administered activity was 139 MBq, and the mean uptake time was 60 min. Gold-standard staging 18F-FDG PET/CT was evaluated if available within 2 wk before or after 68Ga-SSO-120 PET if morphologic differences in CT images were absent. 68Ga-SSO-120- or 18F-FDG-positive lesions were reported in 7 anatomic regions (primary tumor, thoracic lymph node metastases, and distant metastases including pleural, contralateral pulmonary, liver, bone, and other) according to the TNM classification for lung cancer (eighth edition). Consensus TNM staging (derived from CT, endobronchial ultrasound-guided transbronchial needle aspiration, PET, and brain MRI) by a clinical tumor board served as the reference standard. Results: Thirty-one patients were included, 12 with limited and 19 with extensive disease according to the Veterans Administration Lung Study Group classification. 68Ga-SSO-120-positive tumor was detected in all patients (100
%K 68Ga-OPS-202 (Other)
%K 68Ga-SSO-120 (Other)
%K PET (Other)
%K SCLC (Other)
%K SSTR (Other)
%F PUB:(DE-HGF)16
%9 Journal Article
%$ pmid:37474272
%R 10.2967/jnumed.123.265664
%U https://inrepo02.dkfz.de/record/277883